Testosterone as potential treatment and prevention for Diabetes Mellitus Type 2

Clinically, we see a direct correlation with diabetes and low testosterone in men. In terms of cardiovascular disease, men have more than twice the risk of dying from coronary (blood vessel) disease than women. When testosterone is low, the risk factors associated with cardiovascular disease are increased, such as elevated cholesterol, insulin resistance that leads to abdominal weight gain, obesity and increased blood clotting. 


To further show our clinical conclusion, researchers from Australia performed a randomized, double-blind, placebo-controlled, phase 3b trial of over 1000 men aged 54-70 years old qualified by the following: overweight, obese, low serum testosterone concentration without pathological hypogonadism and newly diagnosed  type 2 diabetes. These men were enrolled in a lifestyle program and randomly assigned to receive an IM injection of testosterone or placebo. Over a period of 2 years results showed that testosterone treatment reduced and reversed the proportion of participants with type 2 diabetes significantly compared to the lifestyle group.

We carefully monitor labs for patients on testosterone therapy to comprehensively assess metabolic health, cardiovascular risk and overall hormone health. At The Hormone Zone, we have found that appropriate treatment approaches and maintaining testosterone within physiological levels have not only improved metabolic health for patients in terms of diabetes and insulin resistance, but have improved cardiovascular risk, bone health and decreased mortality and overall increased quality of life.

Contact us to see how you can get your hormone levels checked and learn how we can help you achieve optimal health.

contact us



1.  Njolstad I., et. al. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996;93:450–6.

2.  Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Wittert, Gary et al. The Lancet Diabetes & Endocrinology, Volume 9, Issue 1, 32 - 45